Literature DB >> 26056742

New approaches to HIV vaccine development.

Barton F Haynes1.   

Abstract

Development of a safe and effective vaccine for HIV is a major global priority. However, to date, efforts to design an HIV vaccine with methods used for development of other successful viral vaccines have not succeeded due to HIV diversity, HIV integration into the host genome, and ability of HIV to consistently evade anti-viral immune responses. Recent success in isolation of potent broadly neutralizing antibodies (bnAbs), in discovery of mechanisms of bnAb induction, and in discovery of atypical mechanisms of CD8T cell killing of HIV-infected cells, have opened new avenues for strategies for HIV vaccine design.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26056742      PMCID: PMC4553082          DOI: 10.1016/j.coi.2015.05.007

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  67 in total

1.  Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family.

Authors:  Mattia Bonsignori; Justin Pollara; M Anthony Moody; Michael D Alpert; Xi Chen; Kwan-Ki Hwang; Peter B Gilbert; Ying Huang; Thaddeus C Gurley; Daniel M Kozink; Dawn J Marshall; John F Whitesides; Chun-Yen Tsao; Jaranit Kaewkungwal; Sorachai Nitayaphan; Punnee Pitisuttithum; Supachai Rerks-Ngarm; Jerome H Kim; Nelson L Michael; Georgia D Tomaras; David C Montefiori; George K Lewis; Anthony DeVico; David T Evans; Guido Ferrari; Hua-Xin Liao; Barton F Haynes
Journal:  J Virol       Date:  2012-08-15       Impact factor: 5.103

2.  Polyreactivity and autoreactivity among HIV-1 antibodies.

Authors:  Mengfei Liu; Guang Yang; Kevin Wiehe; Nathan I Nicely; Nathan A Vandergrift; Wes Rountree; Mattia Bonsignori; S Munir Alam; Jingyun Gao; Barton F Haynes; Garnett Kelsoe
Journal:  J Virol       Date:  2014-10-29       Impact factor: 5.103

Review 3.  Role of immune mechanisms in induction of HIV-1 broadly neutralizing antibodies.

Authors:  Laurent Verkoczy; Garnett Kelsoe; M Anthony Moody; Barton F Haynes
Journal:  Curr Opin Immunol       Date:  2011-04-27       Impact factor: 7.486

4.  Vaccine induction of antibodies against a structurally heterogeneous site of immune pressure within HIV-1 envelope protein variable regions 1 and 2.

Authors:  Hua-Xin Liao; Mattia Bonsignori; S Munir Alam; Jason S McLellan; Georgia D Tomaras; M Anthony Moody; Daniel M Kozink; Kwan-Ki Hwang; Xi Chen; Chun-Yen Tsao; Pinghuang Liu; Xiaozhi Lu; Robert J Parks; David C Montefiori; Guido Ferrari; Justin Pollara; Mangala Rao; Kristina K Peachman; Sampa Santra; Norman L Letvin; Nicos Karasavvas; Zhi-Yong Yang; Kaifan Dai; Marie Pancera; Jason Gorman; Kevin Wiehe; Nathan I Nicely; Supachai Rerks-Ngarm; Sorachai Nitayaphan; Jaranit Kaewkungwal; Punnee Pitisuttithum; James Tartaglia; Faruk Sinangil; Jerome H Kim; Nelson L Michael; Thomas B Kepler; Peter D Kwong; John R Mascola; Gary J Nabel; Abraham Pinter; Susan Zolla-Pazner; Barton F Haynes
Journal:  Immunity       Date:  2013-01-11       Impact factor: 31.745

5.  Prevalence of broadly neutralizing antibody responses during chronic HIV-1 infection.

Authors:  Peter Hraber; Michael S Seaman; Robert T Bailer; John R Mascola; David C Montefiori; Bette T Korber
Journal:  AIDS       Date:  2014-01-14       Impact factor: 4.177

6.  Evolution of an HIV glycan-dependent broadly neutralizing antibody epitope through immune escape.

Authors:  Penny L Moore; Elin S Gray; C Kurt Wibmer; Jinal N Bhiman; Molati Nonyane; Daniel J Sheward; Tandile Hermanus; Shringkhala Bajimaya; Nancy L Tumba; Melissa-Rose Abrahams; Bronwen E Lambson; Nthabeleng Ranchobe; Lihua Ping; Nobubelo Ngandu; Quarraisha Abdool Karim; Salim S Abdool Karim; Ronald I Swanstrom; Michael S Seaman; Carolyn Williamson; Lynn Morris
Journal:  Nat Med       Date:  2012-10-21       Impact factor: 53.440

7.  Induction of antibodies in rhesus macaques that recognize a fusion-intermediate conformation of HIV-1 gp41.

Authors:  S Moses Dennison; Laura L Sutherland; Frederick H Jaeger; Kara M Anasti; Robert Parks; Shelley Stewart; Cindy Bowman; Shi-Mao Xia; Ruijun Zhang; Xiaoying Shen; Richard M Scearce; Gilad Ofek; Yongping Yang; Peter D Kwong; Sampa Santra; Hua-Xin Liao; Georgia Tomaras; Norman L Letvin; Bing Chen; S Munir Alam; Barton F Haynes
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240

8.  Viral escape from HIV-1 neutralizing antibodies drives increased plasma neutralization breadth through sequential recognition of multiple epitopes and immunotypes.

Authors:  Constantinos Kurt Wibmer; Jinal N Bhiman; Elin S Gray; Nancy Tumba; Salim S Abdool Karim; Carolyn Williamson; Lynn Morris; Penny L Moore
Journal:  PLoS Pathog       Date:  2013-10-31       Impact factor: 6.823

9.  Immune clearance of highly pathogenic SIV infection.

Authors:  Scott G Hansen; Michael Piatak; Abigail B Ventura; Colette M Hughes; Roxanne M Gilbride; Julia C Ford; Kelli Oswald; Rebecca Shoemaker; Yuan Li; Matthew S Lewis; Awbrey N Gilliam; Guangwu Xu; Nathan Whizin; Benjamin J Burwitz; Shannon L Planer; John M Turner; Alfred W Legasse; Michael K Axthelm; Jay A Nelson; Klaus Früh; Jonah B Sacha; Jacob D Estes; Brandon F Keele; Paul T Edlefsen; Jeffrey D Lifson; Louis J Picker
Journal:  Nature       Date:  2013-09-11       Impact factor: 49.962

10.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Authors:  Morgane Rolland; Paul T Edlefsen; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Tomer Hertz; Allan C deCamp; Chris Carrico; Sergey Menis; Craig A Magaret; Hasan Ahmed; Michal Juraska; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; Jason S McLellan; Ivelin Georgiev; Peter D Kwong; Jonathan M Carlson; Nelson L Michael; William R Schief; Peter B Gilbert; James I Mullins; Jerome H Kim
Journal:  Nature       Date:  2012-09-10       Impact factor: 49.962

View more
  42 in total

Review 1.  The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials.

Authors:  Upal Roy; Jesse Rodríguez; Paul Barber; José das Neves; Bruno Sarmento; Madhavan Nair
Journal:  Nanomedicine (Lond)       Date:  2015-09-24       Impact factor: 5.307

Review 2.  What Are the Most Powerful Immunogen Design Vaccine Strategies? Reverse Vaccinology 2.0 Shows Great Promise.

Authors:  Dennis R Burton
Journal:  Cold Spring Harb Perspect Biol       Date:  2017-11-01       Impact factor: 10.005

Review 3.  Broadly Neutralizing Antibodies to HIV and Their Role in Vaccine Design.

Authors:  Dennis R Burton; Lars Hangartner
Journal:  Annu Rev Immunol       Date:  2016-05-20       Impact factor: 28.527

4.  CXCL13 is a plasma biomarker of germinal center activity.

Authors:  Colin Havenar-Daughton; Madelene Lindqvist; Antje Heit; Jennifer E Wu; Samantha M Reiss; Kayla Kendric; Simon Bélanger; Sudhir Pai Kasturi; Elise Landais; Rama S Akondy; Helen M McGuire; Marcella Bothwell; Parsia A Vagefi; Eileen Scully; Georgia D Tomaras; Mark M Davis; Pascal Poignard; Rafi Ahmed; Bruce D Walker; Bali Pulendran; M Juliana McElrath; Daniel E Kaufmann; Shane Crotty
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-23       Impact factor: 11.205

Review 5.  The mutable vaccine for mutable viruses.

Authors:  Marilia Cascalho; Samuel J Balin; Jeffrey L Platt
Journal:  Immunotherapy       Date:  2017-06       Impact factor: 4.196

6.  The Toughest Nut to Crack: Will We Ever Have a Preventive and Effective HIV-1 Vaccine?

Authors:  Zwi N Berneman
Journal:  Mol Ther       Date:  2016-11       Impact factor: 11.454

7.  T-bet+ B cells are induced by human viral infections and dominate the HIV gp140 response.

Authors:  James J Knox; Marcus Buggert; Lela Kardava; Kelly E Seaton; Michael A Eller; David H Canaday; Merlin L Robb; Mario A Ostrowski; Steven G Deeks; Mark K Slifka; Georgia D Tomaras; Susan Moir; M Anthony Moody; Michael R Betts
Journal:  JCI Insight       Date:  2017-04-20

Review 8.  Antigenic variability: Obstacles on the road to vaccines against traditionally difficult targets.

Authors:  R Servín-Blanco; R Zamora-Alvarado; G Gevorkian; K Manoutcharian
Journal:  Hum Vaccin Immunother       Date:  2016-06-13       Impact factor: 3.452

9.  Environmental exposures are hidden modifiers of anti-viral immunity.

Authors:  Anthony M Franchini; B Paige Lawrence
Journal:  Curr Opin Toxicol       Date:  2018-01-31

10.  Uncommon structural motifs dominate the antigen binding site in human autoantibodies reactive with basement membrane collagen.

Authors:  Mary H Foster; Elizabeth S Buckley; Benny J Chen; Kwan-Ki Hwang; Amy G Clark
Journal:  Mol Immunol       Date:  2016-07-20       Impact factor: 4.407

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.